Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 242

1.

Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.

Sheard MA, Ghent MV, Cabral DJ, Lee JC, Khankaldyyan V, Ji L, Wu SQ, Kang MH, Sposto R, Asgharzadeh S, Reynolds CP.

Exp Cell Res. 2015 May 15;334(1):78-89. doi: 10.1016/j.yexcr.2015.03.024. Epub 2015 Apr 3.

PMID:
25845499
2.

Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.

Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP.

Clin Cancer Res. 2015 Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.

PMID:
25733708
3.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN.

Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.

PMID:
25711293
4.

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ.

Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10.

PMID:
25500058
5.

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. doi: 10.1002/pbc.25329. Epub 2014 Nov 18.

PMID:
25407467
6.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.

Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ.

Pediatr Blood Cancer. 2015 Jan;62(1):91-8. doi: 10.1002/pbc.25201. Epub 2014 Sep 27.

PMID:
25263539
7.

Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.

Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2014 Nov;61(11):1972-9. doi: 10.1002/pbc.25175. Epub 2014 Aug 17.

PMID:
25131802
8.

Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.

Sonawane P, Cho HE, Tagde A, Verlekar D, Yu AL, Reynolds CP, Kang MH.

Br J Pharmacol. 2014 Dec;171(23):5330-44. doi: 10.1111/bph.12846.

PMID:
25039756
9.
10.

Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines.

Ryu Y, Hall CP, Reynolds CP, Kang MH.

Exp Biol Med (Maywood). 2014 Oct;239(10):1390-402. doi: 10.1177/1535370214538745. Epub 2014 Jun 20.

PMID:
24951472
11.

Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.

Farooqi AS, Dagg RA, Choi LM, Shay JW, Reynolds CP, Lau LM.

J Neurooncol. 2014 Aug;119(1):17-26. doi: 10.1007/s11060-014-1456-8. Epub 2014 May 3.

PMID:
24792489
12.

Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study.

Kang MH, Villablanca JG, Glade Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ.

BMC Res Notes. 2014 Apr 23;7:256. doi: 10.1186/1756-0500-7-256.

13.

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.

Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D.

Pediatr Blood Cancer. 2014 Aug;61(8):1493-6. doi: 10.1002/pbc.25026. Epub 2014 Mar 24. Erratum in: Pediatr Blood Cancer. 2014 Sep;61(9):1716. Lyalin, Dmitry [added].

PMID:
24664981
14.

DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development.

Shah ED, Fisch BM, Arceci RJ, Buckley JD, Reaman GH, Sorensen PH, Triche TJ, Reynolds CP.

Cancer Chemother Pharmacol. 2014 May;73(5):1089-93. doi: 10.1007/s00280-014-2433-9. Epub 2014 Mar 25.

PMID:
24663501
15.

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.

Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Aug;61(8):1486-9. doi: 10.1002/pbc.24989. Epub 2014 Feb 20.

PMID:
24623675
16.

Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.

May WA, Grigoryan RS, Keshelava N, Cabral DJ, Christensen LL, Jenabi J, Ji L, Triche TJ, Lawlor ER, Reynolds CP.

PLoS One. 2013 Dec 2;8(12):e80060. doi: 10.1371/journal.pone.0080060. eCollection 2013.

17.

Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 May;61(5):922-4. doi: 10.1002/pbc.24800. Epub 2013 Oct 26.

18.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.

Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R.

Pediatr Blood Cancer. 2014 Feb;61(2):245-52. doi: 10.1002/pbc.24724. Epub 2013 Sep 4.

19.

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Jan;61(1):158-64. doi: 10.1002/pbc.24616. Epub 2013 Aug 19.

20.

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG.

Lancet Oncol. 2013 Sep;14(10):999-1008. doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk